High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

Search Search
Inhaled Medical Aerosols and Respiratory Therapeutic Interventions to Promote Neonatal and Pediatric Lung Health

DiBlasi Lab

The DiBlasi Lab aims to develop and evaluate inhaled therapies and life-support systems for newborns and children with life-threatening respiratory failure. Working with worldwide collaborators, industry partners and clinical staff at Seattle Children's Hospital, the lab conducts innovative pre-clinical research to investigate respiratory therapies and devices' therapeutic benefits and responses to promote gas exchange, lung health, growth and development.

The lab focuses on novel drug delivery formulations and devices for administering inhaled medical aerosols and specialty gases, improving airway secretion clearance and optimizing mechanical ventilation. Laboratory findings have been translated into clinical trials and resulted in several devices and therapies that are currently being used clinically in children. Ultimately, we aim to improve respiratory care for children in all low- and well-resourced clinical settings.

Featured Research

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.